◆ SpookStack

: 82/18/2885 11:43 3816192152 BACT DIV PAGE 16/17 The University of Michigan Medical Center f . Division of Allergy 3918 Taubman Center nit ichigan 48109-0380 Pax (313) 936-2990 December 5, 1997 Bruce Ivins, Ph.D, U.S. Anny Research Institute for Infectious Disease Bacteriology Division 1425 Porter Street Fort Detrick, MD 21762-5077 Dear Dr. Ivins: It was a pleasure speaking with you the other day. I much appreciate your willingness to work with us conceming our new anti-sporicidal material. We are looking forward to deing in vitro evaluating whether or not this material is effective against anthrax spores given its efficacy against other species of bacillus spores. These studies would involve mixing the material with the spores for varying lengths of time and then eithcr separating the spores or culturing them directly to determine the viability. We might also do fixation of the spore preparations to determine if there are any ultrastructure changes in the spores that can be observed with electron microscopy. My technicians are fully trained in the contagious pathogen handling and have experience with level 3 biosafety requirements, They, as J, are willing to undergo both the anthrax and plague immunizations, although I was hoping that we might be able to administer the vaccines at the University of Michigan. This might allow us to only make one trip to USAMRID before we begin the studies. If we could cither purchase the vaccine from you or from a commercial distributor, we would be happy to then administer it and document titers in any way you feel appropriate. I look forward to the initiation of this work. I believe it could be a very interesting collaboration that could eventually lead to animal studies. On December 19, commensurate with the filing of patents on this material, I will send you additional data on the formulations and our studies concerning the ability of these materials to inactivate spores both i» vitro and in vivo. Sincerel: ion ~1 OF oO C)